Progress in the Research of Topical Imiquimod

( views:, downloads: )
Author:
LI Zhi-jun()
LIU Liu()
HE Li()
Journal Title:
INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY
Issue:
Volume 32, Issue 03, 2006
DOI:
Key Word:

Abstract:

  • [1]Barnetson RS,Satchell A,Zhuang L,et al.Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells.Clin Exp Dermatol,2004,29:639-643.
  • [2]Vidal D,Matias-Guiu X,Alomar A.Efficacy of imiquimod for the expression of Bcl-2,Ki67,p53 and basal cell carcinoma apoptosis.Br J Dermatol,2004,151:656-662.
  • [3]Peris K,Campione E,Micantonio T,et al.Imiquimod treatment of superficial and nodular basal cell carcinoma:12-week open-label trial.Dermatol Surg,2005,31:318-323.
  • [4]Smith K J,Hamza S,Skelton H.Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Thl and M1 cytokine pattern.Clin Exp Dermatol,2004,29:505-512.
  • [5]Martin-Garcia RF.Imiquimod:an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma.Dermatol Surg,2005,31:371-374.
  • [6]Wolf IH,Cerroni L,Kodama K,et al.Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.Arch Dermatol,2005,141:510-514.
  • [7]Kamin A,Eigentler TK,Radny P,et al.Imiquimod in the treatment of extensive recurrent lentigo maligna.J Am Acad Dermatol,2005,52(2 Suppl 1):51-52.
  • [8]Schon MP,Wienrich BG,Drewniok C,et al.Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.J Invest Dermatol,2004,122:1266-1276.
  • [9]Hesling C,D' Incan M,Mansard S,et al.In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases.Br J Dermatol,2004,150:761-767.
  • [10]Hazen PG,CarneyJF,Engstrom CW,et al.Proliferating hemangioma of infancy:successful treatment with topical 5% imiquimod cream.Pediatr Dermatol,2005,22:254-256.
  • [11]Welsh O,Olazaran Z,Gomez M,et al.Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream.J Am Acad Dermatol,2004,51:639-642.
  • [12]Martinez MI,Sanchez-Carpintero I,North PE,et al.Infantile hemangioma:clinical resolution with 5% imiquimod cream.Arch Dermatol,2002,138:881-884.
  • [13]Sidbury R,Neuschler N,Neuschler E,et al.Topically applied imiquimod inhibits vascular tumor growth in vivo.J Invest Dermatol,2003,121:1205-1209.
  • [14]Clejan S,Mandrea E,Pandrea Ⅳ,et al.Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections.J Cell Mol Med,2005,9:457-461.
  • [15]Korman N,Moy R,Ling M,et al.Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis:results of two phase 3,randomized,double-blind,parallel-group,vehicle-controlled trials.Arch Dermatol,2005,141:467-473.
  • [16]Szeimies RM,Gerritsen MJ,Gupta G,et al.Imiquimod 5% cream for the treatment of actinic keratosis:results from a phase Ⅲ,randomized,double-blind,vehicle-controlled,clinical trial with histology.J Am Acad Dermatol,2004,51:547-555.
  • [17]Bianchi L,Campione E,Marulli GC,et al.Actinic keratosis treated with an immune response modifier:a case report of six patients.Clin Exp Dermatol,2003,28(Suppl 1):39-41.
  • [18]Lysa B,Tartler U,WolfR,et al.Gene expression in actinic keratoses:pharmacological modulation by imiquimod.Br J Dermatol,2004,151:1150-1159.
  • [19]Jacob SE,Berman B,Nassiri M,et al.Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis.Br J Dermatol,2003,149(Supp166):62-65.
  • [20]Berman B,Villa A.Imiquimod 5% cream for keloid management.Dermatol Surg,2003,29:1050-1051.
  • [21]Prado A,Andrades P,Benitez S,et al.Scar management after breast surgery:preliminary results of a prospective,randomized,and double-blind clinical study with aldara cream 5% (imiquimod).Plast Reconstr Surg,2005,115:966-972.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn